Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
FASEB J ; 25(6): 1836-43, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21321190

RESUMEN

Human endothelial progenitor cells (hEPCs) participate in neovascularization of ischemic tissues. Function and number of hEPCs decline in patients with cardiovascular disease, and therapeutic strategies to enhance hEPC function remain an important field of investigation. The Wnt signaling system, comprising 19 lipophilic proteins, regulates vascular patterning in the developing embryo. However, the effects of Wnts on hEPCs and the adult vasculature remain unclear. We demonstrate here that Wnt1 is expressed in a subset of endothelial cells lining the murine embryonic dorsal aorta and is reactivated in malignant angiosarcoma, suggesting a strong association of Wnt1 with angiogenesis. We investigate the effects of Wnt1 in enhancing hEPC function and blood flow to ischemic tissues and show that Wnt1 enhances the proliferative and angiogenic functions of hEPCs in a hepatocyte growth factor (HGF)-dependent manner. Injection of Wnt1-expressing hEPCs increases blood flow and capillary density in murine ischemic hindlimbs. Furthermore, injection of Wnt1 protein alone similarly increases blood flow and capillary density in ischemic hindlimbs, and this effect is associated with increased HGF expression in ischemic muscle. These findings demonstrate that Wnt1, a marker of neural crest cells and hitherto unknown angiogenic function, is a novel angiogenic protein that is expressed in developing endothelial cells, exerts salutary effects on postnatal hEPCs, and can be therapeutically deployed to increase blood flow and angiogenesis in ischemic tissues.


Asunto(s)
Células Endoteliales/citología , Factor de Crecimiento de Hepatocito/metabolismo , Isquemia/metabolismo , Neovascularización Fisiológica/fisiología , Células Madre/fisiología , Proteína Wnt1/metabolismo , Animales , Aorta/citología , Aorta/efectos de los fármacos , Aorta/embriología , Modelos Animales de Enfermedad , Embrión de Mamíferos/metabolismo , Células Endoteliales/fisiología , Factor de Crecimiento de Hepatocito/genética , Miembro Posterior/irrigación sanguínea , Humanos , Isquemia/etiología , Ratones , Ratones Endogámicos C57BL , Músculo Esquelético/irrigación sanguínea , Enfermedad Arterial Periférica/complicaciones , Enfermedad Arterial Periférica/terapia , Proteína Wnt1/genética
2.
PLoS One ; 8(2): e55757, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23393600

RESUMEN

Ribs are primarily made of cortical bone and are necessary for chest expansion and ventilation. Rib fractures represent the most common type of non-traumatic fractures in the elderly yet few studies have focused on the biology of rib fragility. Here, we show that deletion of ßcatenin in Col1a2 expressing osteoblasts of adult mice leads to aggressive osteoclastogenesis with increased serum levels of the osteoclastogenic cytokine RANKL, extensive rib resorption, multiple spontaneous rib fractures and chest wall deformities. Within days of osteoblast specific ßcatenin deletion, animals die from respiratory failure with a vanishing rib cage that is unable to sustain ventilation. Increased bone resorption is also observed in the vertebrae and femur. Treatment with the bisphosphonate pamidronate delayed but did not prevent death or associated rib fractures. In contrast, administration of the glucocorticoid dexamethasone decreased serum RANKL and slowed osteoclastogenesis. Dexamethasone preserved rib structure, prevented respiratory compromise and strikingly increased survival. Our findings provide a novel model of accelerated osteoclastogenesis, where deletion of osteoblast ßcatenin in adults leads to rapid development of destructive rib fractures. We demonstrate the role of ßcatenin dependent mechanisms in rib fractures and suggest that glucocorticoids, by suppressing RANKL, may have a role in treating bone loss due to aggressive osteoclastogenesis.


Asunto(s)
Corticoesteroides/uso terapéutico , Osteoblastos/metabolismo , Fracturas de las Costillas/tratamiento farmacológico , Fracturas de las Costillas/metabolismo , beta Catenina/metabolismo , Animales , Dexametasona/uso terapéutico , Inmunohistoquímica , Ratones , Osteoblastos/efectos de los fármacos , Fracturas de las Costillas/mortalidad , beta Catenina/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA